A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma
Molecular Oncology · 2026-11 · 20 (11) · 2741-2763
DOI: 10.1002/1878-0261.70274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 27.05.2026. Verfasst von Patryk Rurka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physics, University of Silesia in Katowice, Chorzów, Poland. Hauptthemen laut MEDLINE: Glioblastoma, Quinazolinones, Glucose, Receptor, Insulin. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
Aberrant signaling through insulin‐like growth factor 1 receptor (IGF1R) and epidermal growth factor receptor (EGFR) drives glioblastoma (GBM) progression and therapy resistance. Herein, we describe the synthesis and biological evaluation of W1B, a novel styrylquinazolinone‐based small‐molecule inhibitor. In antiproliferative assays, W1B exhibited potent submicromolar activity against a panel of GBM cell lines. Kinase assays and binding studies confirmed strong inhibition and high binding affinity toward IGF1R. Molecular docking suggested possible interactions with both IGF1R and EGFR, with W1B adopting distinct binding poses in each kinase domain. In cellular studies, W1B reduced IGF1R and EGFR protein levels in LN229 cells and suppressed Akt phosphorylation. Under high‐glucose conditions, however, W1B only retained inhibitory activity toward IGF1R, resulting in attenuated effects on the Akt/mTOR axis and underscoring the influence of glucose‐dependent signaling rewiring on drug efficacy. Combination studies revealed that W1B acts synergistically with the EGFR inhibitor dacomitinib, effectively overcoming compensatory activation of parallel pathways. Biomimetic lipophilicity and in silico pharmacokinetic analyses indicated that styrylquinazolinone has the potential to cross the blood–brain barrier (BBB). The in vivo studies on Danio rerio have shown a good safety profile, as well as strong antitumor potential of the tested compound. Therefore, these findings establish W1B as a promising derivative for the development of next‐generation dual IGF1R/EGFR inhibitors in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Physics, University of Silesia in Katowice, Chorzów, Poland.
- Institute of Chemistry, University of Silesia in Katowice, Chorzów, Poland.
- Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Kraków, Poland.
- Department of Biopharmacy, Medical University of Lublin, Poland.
- Department of Physical Chemistry, Institute of Chemical Sciences, Maria Curie-Skłodowska University in Lublin, Poland.
- Department of Medical Chemistry, Medical University of Lublin, Poland.
ORCID-Profile: Mateusz Jasica, Katarzyna Malarz
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Rurka, P., Cieślik, W., Płaziński, W., Stępnik, K., Boguszewska-Czubara, A., Kot, E., Musioł, R., Jasica, M., Mrozek-Wilczkiewicz, A., & Malarz, K. (2026). A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma. Molecular Oncology, 20(11), 2741-2763. https://doi.org/10.1002/1878-0261.70274
Vancouver
Rurka P, Cieślik W, Płaziński W, Stępnik K, Boguszewska-Czubara A, Kot E, et al. A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma. Molecular Oncology. 2026;20(11):2741-2763. doi:10.1002/1878-0261.70274
BibTeX
@article{Rurka2026,
author = {Rurka, Patryk and Cieślik, Wioleta and Płaziński, Wojciech and Stępnik, Katarzyna and Boguszewska-Czubara, Anna and Kot, Elżbieta and Musioł, Robert and Jasica, Mateusz and Mrozek-Wilczkiewicz, Anna and Malarz, Katarzyna},
title = {A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {11},
pages = {2741--2763},
doi = {10.1002/1878-0261.70274}
}
EUVIMED